AFB testing of joint tissue (native and prosthetic revisions) will only be performed if requested with appropriate clinical details (patients receiving immunosuppressive therapy, patients who failed to respond to antibacterial therapy, patients with recent intraarticular injections or a history of significant open joint trauma with chronic symptoms of infection and patients with risk factors for tuberculosis) or by microbiologist consult.

Recommendations:
The Canadian Tuberculosis Standards states that:
"Every effort should be made to obtain clinical samples for both mycobacteriologic (acid-fast bacilli smear, culture, nucleic acid amplification test) and histopathologic tests. If the specimen is insufficient for all testing, mycobacterial culture should be prioritized given it has the highest diagnostic yield and allows for gold-standard phenotypic drug testing.”
“Every person with presumed extra-pulmonary TB should also be assessed for pulmonary TB to assess infectiousness and potentially assist with diagnosis.”
“In general, tissue has a higher yield than liquid/biologic fluids.”
 
Shared Health Testing Process - Every AFB tissue culture is evaluated by microscopy and culture. Smears are reported semi-quantitatively (Negative or 1+ to 4+). Cultures are incubated for 7 weeks and reported as soon as growth is detected.
All microscopy smear positive AFB samples receive nucleic acid amplification testing (NAAT). The in-house NAAT detects M. tuberculosis and Mycobacterium spp. AFB smear negative samples require a microbiologist consult if a NAAT is required.
Susceptibility testing for M. tuberculosis is performed routinely by the NRCM-NML. Susceptibility testing for nontuberculous mycobacteria may be requested by consultation with the Shared Health Microbiologist-on-call.
If Mycobacterium ulcerans is suspected clinically, the laboratory must be notified as prolonged culture incubations may be required.

Patient Preparation Instructions:
Patients' sample collection should be conducted in accordance with Infection and Control Practices. The WRHA Acute Infection Prevention and Control Manual states that "when collecting specimens for suspected or active TB, specimens must be collected utilizing Airborne Precautions regardless of age".
Accurate patient identification must be made prior to sample collection.  Patient identification should be done in accordance with site policy.
Samples and requisitions must be labeled/completed in accordance with the Shared Health Specimen Acceptance Policy.